Credelio Plus

Country: European Union

Language: Spanish

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

lotilaner, milbemycin oxime

Available from:

Elanco GmbH

ATC code:

QP54AB51

INN (International Name):

lotilaner / milbemycin oxime

Therapeutic group:

Perros

Therapeutic area:

Endectocidas

Therapeutic indications:

For use in dogs with, or at risk from, mixed infestations/infections of ticks, fleas, gastrointestinal nematodes, heartworm and/or lungworm.

Authorization status:

Autorizado

Authorization date:

2021-04-14

Patient Information leaflet

                                18
B.
PROSPECTO
19
PROSPECTO:
CREDELIO PLUS 56,25 MG/2,11 MG COMPRIMIDOS MASTICABLES PARA PERROS
(1,4‒2,8 KG)
CREDELIO PLUS 112,5 MG/4,22 MG COMPRIMIDOS MASTICABLES PARA PERROS
(>2,8‒5,5 KG)
CREDELIO PLUS 225 MG/8,44 MG COMPRIMIDOS MASTICABLES PARA PERROS
(>5,5‒11 KG)
CREDELIO PLUS 450 MG/16,88 MG COMPRIMIDOS MASTICABLES PARA PERROS
(>11‒22 KG)
CREDELIO PLUS 900 MG/33,75 MG COMPRIMIDOS MASTICABLES PARA PERROS
(>22‒45 KG)
1.
NOMBRE O RAZÓN SOCIAL Y DOMICILIO O SEDE SOCIAL DEL TITULAR DE
LA AUTORIZACIÓN DE COMERCIALIZACIÓN Y DEL FABRICANTE
RESPONSABLE DE LA LIBERACIÓN DE LOS LOTES, EN CASO DE QUE SEAN
DIFERENTES
Titular de la autorización de comercialización:
Elanco GmbH
Heinz-Lohmann-Str. 4
27472, Cuxhaven
Alemania
Fabricante responsable de la liberación del lote:
Elanco France S.A.S
26 Rue de la Chapelle
68330, Huningue
Francia
2.
DENOMINACIÓN DEL MEDICAMENTO VETERINARIO
Credelio Plus 56,25 mg/2,11 mg comprimidos masticables para perros
(1,4‒2,8 kg)
Credelio Plus 112,5 mg/4,22 mg comprimidos masticables para perros
(>2,8‒5,5 kg)
Credelio Plus 225 mg/8,44 mg comprimidos masticables para perros
(>5,5‒11 kg)
Credelio Plus 450 mg/16,88 mg comprimidos masticables para perros
(>11‒22 kg)
Credelio Plus 900 mg/33,75 mg comprimidos masticables para perros
(>22‒45 kg)
3.
COMPOSICIÓN CUALITATIVA Y CUANTITATIVA DE LA(S) SUSTANCIA(S)
ACTIVA(S) Y OTRA(S) SUSTANCIA(S)
Cada comprimido masticable contiene:
CREDELIO PLUS COMPRIMIDOS
MASTICABLES
LOTILANER (MG)
MILBEMICINA OXIMA (MG)
para perros (1,4‒2,8 kg)
56,25
2,11
para perros (>2,8‒5,5 kg)
112,5
4,22
para perros (>5,5‒11 kg)
225
8,44
para perros (>11‒22 kg)
450
16,88
para perros (>22‒45 kg)
900
33,75
Comprimido masticable biconvexo redondo de blanco a beige con manchas
de color marrón.
4.
INDICACIÓN(ES) DE USO
Para usar en perros con infestaciones/infecciones mixtas de
garrapatas, pulgas, nematodos
20
gastrointestinales, dirofilarias o parásitos pulmonares, o con riesgo
de padecerlas. Este medicamento
veterinario está indicado para su 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANEXO I
FICHA TÉCNICA O RESUMEN DE LAS CARACTERÍSTICAS DEL PRODUCTO
2
1.
DENOMINACIÓN DEL MEDICAMENTO VETERINARIO
Credelio Plus 56,25 mg/2,11 mg comprimidos masticables para perros
(1,4‒2,8 kg)
Credelio Plus 112,5 mg/4,22 mg comprimidos masticables para perros
(>2,8‒5,5 kg)
Credelio Plus 225 mg/8,44 mg comprimidos masticables para perros
(>5,5‒11 kg)
Credelio Plus 450 mg/16,88 mg comprimidos masticables para perros
(>11‒22 kg)
Credelio Plus 900 mg/33,75 mg comprimidos masticables para perros
(>22‒45 kg)
2.
COMPOSICIÓN CUALITATIVA Y CUANTITATIVA
SUSTANCIAS ACTIVAS:
Cada comprimido masticable contiene:
Para la lista completa de excipientes, véase la sección 6.1.
3.
FORMA FARMACÉUTICA
Comprimido masticable.
Comprimido masticable biconvexo redondo de blanco a beige con manchas
de color marrón y bordes
biselados con la letra “I” en relieve a un lado del comprimido.
4.
DATOS CLÍNICOS
4.1
ESPECIES DE DESTINO
Perros
4.2
INDICACIONES DE USO, ESPECIFICANDO LAS ESPECIES DE DESTINO
Para usar en perros con infestaciones/infecciones mixtas de
garrapatas, pulgas, nematodos
gastrointestinales, dirofilarias o parásitos pulmonares, y/o con
riesgo de padecerlas.
Este medicamento veterinario está indicado para su uso cuando se
requiera simultáneamente el
tratamiento contra las garrapatas/pulgas y los nematodos
gastrointestinales o el tratamiento contra las
garrapatas/pulgas y la prevención de
dirofilariasis/angiostrongilosis.
Garrapatas y pulgas
Para el tratamiento de infestaciones de garrapatas (
_Dermacentor reticulatus, Ixodes ricinus, _
_Rhipicephalus sanguineus _
e
_ I. hexagonus_
) y pulgas (
_Ctenocephalides felis _
y
_C. canis_
) en perros.
Este medicamento veterinario proporciona una eliminación inmediata y
persistente de la actividad
durante 1 mes para garrapatas y pulgas.
El medicamento veterinario se puede utilizar como parte de una
estrategia de tratamiento para el
control de la dermatitis alérgica por pulgas (DAP).
CREDELIO PLUS COMPRIMIDOS
LOTILANER
MILBEMICINA OXIMA
Perros (1,4‒2,8 kg
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-08-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-08-2021
Public Assessment Report Public Assessment Report Bulgarian 04-08-2021
Patient Information leaflet Patient Information leaflet Czech 04-08-2021
Public Assessment Report Public Assessment Report Czech 04-08-2021
Patient Information leaflet Patient Information leaflet Danish 04-08-2021
Public Assessment Report Public Assessment Report Danish 04-08-2021
Patient Information leaflet Patient Information leaflet German 04-08-2021
Public Assessment Report Public Assessment Report German 04-08-2021
Patient Information leaflet Patient Information leaflet Estonian 04-08-2021
Public Assessment Report Public Assessment Report Estonian 04-08-2021
Patient Information leaflet Patient Information leaflet Greek 04-08-2021
Public Assessment Report Public Assessment Report Greek 04-08-2021
Patient Information leaflet Patient Information leaflet English 04-08-2021
Public Assessment Report Public Assessment Report English 04-08-2021
Patient Information leaflet Patient Information leaflet French 04-08-2021
Public Assessment Report Public Assessment Report French 04-08-2021
Patient Information leaflet Patient Information leaflet Italian 04-08-2021
Public Assessment Report Public Assessment Report Italian 04-08-2021
Patient Information leaflet Patient Information leaflet Latvian 04-08-2021
Public Assessment Report Public Assessment Report Latvian 04-08-2021
Patient Information leaflet Patient Information leaflet Lithuanian 04-08-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-08-2021
Public Assessment Report Public Assessment Report Lithuanian 04-08-2021
Patient Information leaflet Patient Information leaflet Hungarian 04-08-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 04-08-2021
Public Assessment Report Public Assessment Report Hungarian 04-08-2021
Patient Information leaflet Patient Information leaflet Maltese 04-08-2021
Public Assessment Report Public Assessment Report Maltese 04-08-2021
Patient Information leaflet Patient Information leaflet Dutch 04-08-2021
Public Assessment Report Public Assessment Report Dutch 04-08-2021
Patient Information leaflet Patient Information leaflet Polish 04-08-2021
Public Assessment Report Public Assessment Report Polish 04-08-2021
Patient Information leaflet Patient Information leaflet Portuguese 04-08-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 04-08-2021
Public Assessment Report Public Assessment Report Portuguese 04-08-2021
Patient Information leaflet Patient Information leaflet Romanian 04-08-2021
Public Assessment Report Public Assessment Report Romanian 04-08-2021
Patient Information leaflet Patient Information leaflet Slovak 04-08-2021
Public Assessment Report Public Assessment Report Slovak 04-08-2021
Patient Information leaflet Patient Information leaflet Slovenian 04-08-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 04-08-2021
Public Assessment Report Public Assessment Report Slovenian 04-08-2021
Patient Information leaflet Patient Information leaflet Finnish 04-08-2021
Public Assessment Report Public Assessment Report Finnish 04-08-2021
Patient Information leaflet Patient Information leaflet Swedish 04-08-2021
Public Assessment Report Public Assessment Report Swedish 04-08-2021
Patient Information leaflet Patient Information leaflet Norwegian 04-08-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 04-08-2021
Patient Information leaflet Patient Information leaflet Icelandic 04-08-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 04-08-2021
Patient Information leaflet Patient Information leaflet Croatian 04-08-2021
Public Assessment Report Public Assessment Report Croatian 04-08-2021

Search alerts related to this product

View documents history